Adaptimmune Therapeutics (NASDAQ:ADAP) Shares Cross Below Fifty Day Moving Average - Here's What Happened

Adaptimmune Therapeutics plc (NASDAQ:ADAP - Get Free Report)'s share price passed below its 50 day moving average during trading on Monday . The stock has a 50 day moving average of $0.60 and traded as low as $0.57. Adaptimmune Therapeutics shares last traded at $0.60, with a volume of 613,593 shares traded.

Analyst Ratings Changes

Several research analysts have recently weighed in on the stock. Guggenheim dropped their target price on shares of Adaptimmune Therapeutics from $4.00 to $3.00 and set a "buy" rating on the stock in a research report on Friday, November 15th. StockNews.com downgraded shares of Adaptimmune Therapeutics from a "strong-buy" rating to a "buy" rating in a research report on Thursday, November 14th. Mizuho lowered their price objective on shares of Adaptimmune Therapeutics from $3.00 to $1.50 and set an "outperform" rating on the stock in a research report on Wednesday, November 27th. Finally, HC Wainwright lowered their price objective on shares of Adaptimmune Therapeutics from $4.00 to $3.50 and set a "buy" rating on the stock in a research report on Thursday, November 14th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Adaptimmune Therapeutics currently has an average rating of "Buy" and an average price target of $2.79.

Adaptimmune Therapeutics Price Performance

The stock's 50-day moving average is $0.60 and its 200 day moving average is $0.81. The stock has a market capitalization of $147.90 million, a PE ratio of -2.63 and a beta of 2.42. The company has a quick ratio of 3.82, a current ratio of 3.85 and a debt-to-equity ratio of 0.62.

Institutional Trading of Adaptimmune Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Baillie Gifford & Co. lifted its stake in Adaptimmune Therapeutics by 10.7% in the third quarter. Baillie Gifford & Co. now owns 16,775,860 shares of the biotechnology company's stock valued at $15,944,000 after acquiring an additional 1,626,657 shares during the last quarter. Jane Street Group LLC lifted its stake in Adaptimmune Therapeutics by 130.4% in the third quarter. Jane Street Group LLC now owns 174,157 shares of the biotechnology company's stock valued at $166,000 after acquiring an additional 98,581 shares during the last quarter. GSA Capital Partners LLP acquired a new stake in Adaptimmune Therapeutics in the third quarter valued at approximately $95,000. Virtu Financial LLC lifted its stake in Adaptimmune Therapeutics by 27.5% in the third quarter. Virtu Financial LLC now owns 101,008 shares of the biotechnology company's stock valued at $96,000 after acquiring an additional 21,769 shares during the last quarter. Finally, FMR LLC lifted its stake in Adaptimmune Therapeutics by 3.0% in the third quarter. FMR LLC now owns 1,740,900 shares of the biotechnology company's stock valued at $1,655,000 after acquiring an additional 50,419 shares during the last quarter. 31.37% of the stock is currently owned by institutional investors and hedge funds.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.